Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aeglea Bio Therapeutics stock

Learn how to easily invest in Aeglea Bio Therapeutics stock.

Aeglea Bio Therapeutics Inc is a biotechnology business based in the US. Aeglea Bio Therapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea Bio Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aeglea Bio Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AGLE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aeglea Bio Therapeutics stock price (NASDAQ: AGLE)

Use our graph to track the performance of AGLE stocks over time.

Aeglea Bio Therapeutics shares at a glance

Information last updated 2022-06-24.
Latest market close$0.55
52-week range$0.59 - $8.50
50-day moving average $1.32
200-day moving average $4.11
Wall St. target price$4.43
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.09

Buy Aeglea Bio Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aeglea Bio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeglea Bio Therapeutics price performance over time

Historical closes compared with the close of $0.5455 from 2022-06-28

1 week (2022-06-20) N/A
1 month (2022-05-31) -65.47%
3 months (2022-03-28) N/A
6 months (2021-12-31) -88.52%
1 year (2021-07-01) -92.35%
2 years (2020-07-01) -94.15%
3 years (2019-07-01) 6.84
5 years (2017-06-30) 3.85

Aeglea Bio Therapeutics financials

Revenue TTM $20.1 million
Gross profit TTM $-38,330,000
Return on assets TTM -36.41%
Return on equity TTM -77.69%
Profit margin 0%
Book value $1.25
Market capitalisation $39.2 million

TTM: trailing 12 months

Aeglea Bio Therapeutics share dividends

We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.

Aeglea Bio Therapeutics share price volatility

Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $0.585 up to $8.5. A popular way to gauge a stock's volatility is its "beta".

AGLE.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 1.5957. This would suggest that Aeglea Bio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea Bio Therapeutics overview

Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.

Frequently asked questions

What percentage of Aeglea Bio Therapeutics is owned by insiders or institutions?
Currently 2.004% of Aeglea Bio Therapeutics shares are held by insiders and 73.816% by institutions.
How many people work for Aeglea Bio Therapeutics?
Latest data suggests 99 work at Aeglea Bio Therapeutics.
When does the fiscal year end for Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics's fiscal year ends in December.
Where is Aeglea Bio Therapeutics based?
Aeglea Bio Therapeutics's address is: 805 Las Cimas Parkway, Austin, TX, United States, 78746
What is Aeglea Bio Therapeutics's ISIN number?
Aeglea Bio Therapeutics's international securities identification number is: US00773J1034
What is Aeglea Bio Therapeutics's CUSIP number?
Aeglea Bio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00773J103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site